ODM-201 crystalline form, preparation method therefor, and pharmaceutical composition thereof
AssigneeHangzhou SoliPharma Co., Ltd.
InventorsXiaohong Sheng, Xiaoxia Sheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to a crystalline form of N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)prop-2-yl)-5-(1-hydroxylethyl)-1H-pyrazole-3-carboxamide (namely, ODM-201). The ODM-201 crystalline form of the present invention has one or more improved properties compared to known ODM-201. The present invention further relates to a method for preparing the ODM-201 crystalline form, a pharmaceutical composition thereof, and a use thereof in the preparation of a medicament for the treatment of nuclear receptor, specifically steroid receptor, and more specifically androgen receptor (AR)-dependent diseases and conditions.
Claims20
Form 4 of N-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)prop-2-yl)-5-(1-hydroxylethyl)-1H-pyrazole-3-carboxamide (ODM -201), wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the ODM -201 Form 4, expressed as 2θ angles, comprises the following characteristic peaks:
- 7.8° ±0.2° , 9.2° ±0.2° , 11.2° ±0.2° and 14.5° ±0.2° .
Form 5 of N-((s)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)prop-2-yl)-5-(1-hydroxylethyl)-1H-pyrazole-3-carboxamide (ODM -201), wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the ODM -201 Form 5, expressed as 2θ angles, comprises the following characteristic peaks:
- 9.2° ±0.2° , 13.6° ±0.2° , 14.4° ±0.2° , 14.6° ±0.2° , 15.5° ±0.2° and 16.8° ±0.2° .
Dependencies are inferred from the claim text.